FIELD: medicine.
SUBSTANCE: group of inventions relates to determination of bacteria activity levels in lungs of patients. Group of inventions discloses method for prediction of enhancing bacterial activity level of Pseudomonas aeruginosa in lungs, as well as method of determining clinical effectiveness in antibiotic treatment of bacterial infection of lungs, caused by Pseudomonas aeruginosa, in which levels of markers of iron capture process by bacteria (for example, siderophores) and levels of bacterial proteins secretion are measured over time. Methods according to present invention are characterized by reliability and high sensitivity.
EFFECT: present group of inventions is especially suitable for determining levels of Pseudomonas aeruginosa activity in lungs of patients suffering from cystic fibrosis.
16 cl, 13 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING PULMONARY BACTERIAL INFECTION WITH APPLICATION OF FLUOROQUINOLONES | 2010 |
|
RU2535056C2 |
| METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF ACUTE COMPLICATIONS USING POLYCLONAL IMMUNOGLOBULIN | 2019 |
|
RU2806443C2 |
| USING LEVOFLOXACIN IN AEROSOL FORM FOR TREATING MUCOVISCIDOSIS | 2010 |
|
RU2563809C2 |
| METHOD OF TREATING PULMONARY DISEASES WITH LIPOSOMAL AMIKACIN FORMULATIONS | 2009 |
|
RU2537238C2 |
| METHOD FOR THE TREATMENT AND PREVENTION OF RECURRENCE OF NOSOCOMIAL PNEUMONIA | 2021 |
|
RU2794585C2 |
| BIOMARKERS FOR TUBERCULOSIS | 2014 |
|
RU2697549C2 |
| METHOD OF TREATING INFECTIOUS DISEASES USING A COMPOSITION COMPRISING A PLASMA DERIVED IMMUNOGLOBULIN M (IGM) | 2016 |
|
RU2731108C2 |
| ALPHA-1 PROTEINASE INHIBITOR FOR DELAY OF BEGINNING OR PROGRESS OF PULMONARY EXACERBATIONS | 2012 |
|
RU2635482C2 |
| TRIASOL COMPOUNDS FOR TREATMENT OF BIOFILM FORMATION | 2008 |
|
RU2478385C2 |
| DIAGNOSING INFECTIOUS AIRWAY DISEASE USING BLOOD SAMPLES | 2012 |
|
RU2723554C2 |
